- General Dermatology
- Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
Israel OKs testing of new melanoma treatment
South San Francisco, Calif. - Israel’s Ministry of Health has granted approval for biopharmaceutical firm Pain Therapeutics Inc., based here, to begin human testing of a new treatment for metastatic melanoma.
South San Francisco, Calif. - Israel’s Ministry of Health has granted approval for biopharmaceutical firm Pain Therapeutics Inc., based here, to begin human testing of a new treatment for metastatic melanoma.
Internet news source MedicalNewsToday.com reports that Pain Therapeutics’ phase 1 study will evaluate the pharmacokinetics of a proprietary radio-labeled monoclonal antibody in patients diagnosed with metastatic melanoma. The company expects to initiate this first-in-human phase 1 study in a limited number of patients in the second quarter of this year at several academic medical centers in Israel.
